IP Library Granted Patent US 9,695,451
Granted Patent B2
US 9,695,451 · App. 15/286,900 · Granted Jul 4, 2017

Polynucleotides encoding engineered imine reductases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,695,451
App. No.
15/286,900
Granted
Jul 4, 2017
Kind
B2
Abstract

The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Claims (22)

1. An engineered polynucleotide encoding an engineered polypeptide having imine reductase activity, wherein said engineered polypeptide has at least 90% sequence identity to SEQ ID NO:2, wherein the amino acid residue at the position corresponding to position 198 of SEQ ID NO:2 has been replaced with an aliphatic, non-polar, polar, or acidic residue.

2. The engineered polynucleotide of claim 1 , wherein said engineered polypeptide has at least 90% sequence identity to SEQ ID NO: 2 and comprises an alanine, histidine, proline, serine, or glutamic acid at the position corresponding to position 198 of SEQ ID NO: 2.

3. The engineered polynucleotide of claim 1 , wherein said engineered polypeptide is capable of converting substrate compound (1a) pyruvate,

and substrate compound (2b) butylamine

to product compound (3b), N-2-(butylamino)propanoic acid,

under suitable reaction conditions.

4. The engineered polynucleotide of claim 1 , wherein said engineered polypeptide is capable of converting substrate compound (1b) cyclohexanone,

and substrate compound (2a) L-norvaline

to product compound (3c), (S)-2-(cyclohexylamino)pentanoic acid,

under suitable reaction conditions.

5. The engineered polynucleotide of claim 1 , wherein said engineered polypeptide is capable of converting substrate compound (1b) cyclohexanone,

and substrate compound (2b) butylamine

to product compound (3d), N-butylcyclohexanamine,

under suitable reaction conditions.

6. The engineered polynucleotide of claim 1 , wherein said engineered polypeptide is capable of converting substrate compound (1i),

and substrate compound (2b)

to product compound (3n),

under suitable reaction conditions.

7. The engineered polynucleotide of claim 1 , wherein said engineered polypeptide is capable of converting substrate compound (1j),

and substrate compound (2b)

to product compound (3o),

under suitable reaction conditions.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →